comparemela.com

ஜோடி போஃபா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Epidemiologist answers common questions around the Covid-19 vaccine

Epidemiologist answers common questions around the Covid-19 vaccine
kfm.co.za - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kfm.co.za Daily Mail and Mail on Sunday newspapers.

We re not vaccinating – a 3rd wave of Covid-19 infections is thus inevitable

We’re not vaccinating – a 3rd wave of Covid-19 infections is thus inevitable 5 May 2021 8:54 AM Share This: The vaccines aren t out there. We’re going to get it, says Dr Jody Boffa. We’re facing a bleak winter, concurs Fatima Hassan. The apocalyptic situation in India and new data from the NICD have South Africans on edge. A third wave of Covid-19 infections is looming. NICD data does not predict when the wave may start, but what it may look like. When will a third wave of Covid-19 infections hit South Africa? (Image by Schäferle from Pixabay.) Waning immunity from previous waves

Vaccines will have to be cheaper and easier to produce as more enter market

Vaccines will have to be cheaper and easier to produce as more enter market
capetalk.co.za - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from capetalk.co.za Daily Mail and Mail on Sunday newspapers.

Why was the AstraZeneca COVID vaccine put on hold? Top Epidemiologist explains

Why was the AstraZeneca COVID vaccine put on hold? Top Epidemiologist explains To answer these questions and more, Kfm Mornings called up top Epidemiologist, Dr Jody Boffa. South Africa has put a hold on the rollout of the AstraZeneca COVID-19 vaccine. Early scientific data released on Sunday revealed that the vaccine offered minimal protection against mild disease for people infected with the second variant of the coronavirus discovered at the end of last year. The new data suggests that in terms of preventing mild to moderate covid, it s only got about a 22% efficacy which is far from the 60% that we would like to see for a mass roll-out and to get to herd immunity eventually.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.